Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nasdaq requires 3 MM’s I believe. According to earlier posts today, I think it was cowtown, we had 3 today.
That’s what I was thinking! The big boys are ready and waiting.
HMHC chart looking good this morning. Maybe leak on earnings.
Not sure if this was posted already:
Timothy Morris Joins Humanigen as Chief Operating Officer and Chief Financial Officer
Aug. 03, 2020 7:00 AM ETBusiness WireHumanigen, Inc. (HGEN)
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (HGEN), (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.
Mr. Morris has more than two decades of experience serving in executive roles at public biotechnology companies. He most recently served as Chief Financial Officer of Iovance, leading the company’s raise of over $1 billion in equity, including a recent $600 million secondary offering. During his career, he has raised more than $2 billion in equity and related offerings, completed over 75 corporate transactions valued in excess of $4 billion, including licensing, mergers and acquisitions, debt offerings and strategic collaborations. In addition to his CFO responsibilities, Mr. Morris will be responsible for manufacturing and supply chain, corporate and business development, investor and public relations and human resources.
Mr. Morris has been a member of the Humanigen Board of Directors since 2016. In connection with this appointment, he has stepped down from his Board position at the company.
“I am honored to join the Humanigen management team and look forward to helping advance our pivotal Phase III clinical trial for lenzilumab in COVID-19 patients as we plan for registration and potential commercialization, as well as continue to accelerate our deep pipeline,” stated Mr. Morris.
“We are delighted that Tim has joined our leadership team at such an important time for the company,” said Dr. Durrant. “We believe that his track record of accomplishments, combined with his capital markets expertise and extensive knowledge of the company, will be indispensable as Humanigen prepares for its next phase of growth as a potential commercial organization.”
Well said!
And don’t forget GILD has been doing collaborations with Lenz for a couple of years now. They know this product and I’m sure they gave their two cents.
Precisely! This is the definition of America. Anyone from anywhere can come out of the ashes and impact the whole world. This is what we do!
Not good for OPKO...
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("Sorrento") today announced it has entered into a licensing agreement with Columbia University ("Columbia") for the rights to a rapid, one-step diagnostic test that detects SARS-CoV-2 virus in as little as 30 minutes from a sample of saliva. Unlike other commercially available diagnostic products, the test developed by Columbia's team, to be marketed by Sorrento under the COVI-TRACE™ name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point of care, on-site or potentially at-home testing.
SLRX to expand clinical trials to additional sarcomas.
https://www.globenewswire.com/news-release/2020/07/29/2069783/0/en/Salarius-Pharmaceuticals-to-Expand-Clinical-Program-to-Target-Additional-Sarcomas-in-Ewing-Sarcoma-Phase-1-2-Clinical-Trial.html
Seriously. It was up like 250% in premarket. Stopped watching after that. We should have picked up on this beforehand. Trump gave the same deal to Fuji the day prior.
Just look at Moderna. Their share price was around $16 before they started getting media coverage. They almost touched $100 about a week ago.
Yup! That’s 1200+ employees!
$GILD may be eying HGEN already.
Lenz and Yescarta collab. since 2018
Lenz and Remdesivir collab since yesterday. LOL
Only makes sense. Really.
I did not sell one share on the spike today.
I have not put a ton of time into that one as most of my funds are invested in HGEN.
BSRC 40% turn around today. Nice volume 30 mil. Maybe some updates coming.
SLRX moves corporate office to Texas medical center and opens new laboratory at J&J’s JLAB!!
Lots of news been coming out here!!
https://www.globenewswire.com/news-release/2020/07/28/2068628/0/en/Salarius-Pharmaceuticals-Announces-Move-to-New-Corporate-Offices-at-Texas-Medical-Center.html
SLRX moves corporate office to Texas medical center and opens new laboratory to J&J’s JLAB!! Lots of changes happening here!
Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center https://seekingalpha.com
Why is Nomis selling if we’re on the verge of $10 plus?
LOL! You think so?
TDA - bid is more than the ask.
You’re right on time.
Hi all, I’m new to this board. Does anyone know the details of the $13 mill share offering from May? Have all the shares been added to the outstanding already?
There’s tons of useful and informative facts in both articles.
Why barf? That was a nice call.
Well now they’re calling for a triple from April’s price range!
Eyeing Up An Earnings Trade In OPKO Health https://seekingalpha.com/article/4359764-eyeing-up-earnings-trade-in-opko-health
Eyeing Up An Earnings Trade In OPKO Health https://seekingalpha.com/article/4359764-eyeing-up-earnings-trade-in-opko-health
OPKO Health Is Likely To Double From Here https://seekingalpha.com/article/4359487-opko-health-is-likely-to-double-from
OPKO Health Is Likely To Double From Here https://seekingalpha.com/article/4359487-opko-health-is-likely-to-double-from
VTGN (M/C ~ $50M)...A Bit of Specifics
*May 2, 2020 5:41 AM ET|About: VistaGen Therapeutics, Inc. (VTGN)|By: Gaurav Batavia, SA News Editor
VistaGen Therapeutics (OTC:VTGN) has filed a prospectus for a 13.1M common shares from stockholders.
7/23
(1)...VistaGen Therapeutics reports 'positive' meeting with FDA regarding PH94B study 08:11 VTGN VistaGen Therapeutics announced the results of a positive meeting with the U.S. FDA regarding Phase 3 development of PH94B for the acute treatment of anxiety in adult patients with social anxiety disorder. VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD. "Much like a rescue inhaler is used in an asthma attack or a migraine drug is used in an acute migraine episode, PH94B is a potential fit for the acute treatment of anxiety symptoms in anticipation of an often predictable, anxiety-provoking situation for individuals suffering from SAD," said Shawn Singh, CEO of VistaGen. "Notably, the FDA concurred that our initial pivotal Phase 3 efficacy study may be conducted in a manner substantially similar to the highly statistically significant Phase 2 study of PH94B, which study involved a single event, laboratory-simulated public speaking challenge in adult patients with SAD. The FDA's specific guidance will enable us to simplify the process of assessing efficacy among SAD patients in our Phase 3 studies and contribute to significant time- and cost-efficiency in the clinic," Singh added.
6/25
VistaGen Therapeutics and EverInsight Therapeutics announced they have entered into a strategic licensing and collaboration agreement for the clinical development and commercialization of PH94B, VistaGen's novel, rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders, in Greater China, South Korea and Southeast Asia. In December 2019, VistaGen received Fast Track designation from the U.S. FDA for development of PH94B for treatment of social anxiety disorder, the FDA's first Fast Track designation for a SAD drug candidate. The goal of the collaboration is to advance and support Phase 3 development and commercialization of PH94B as a potentially groundbreaking anti-anxiety medicine for patients in Greater China and other important Asian markets. Under the terms of the agreement, EverInsight will be responsible for clinical development, regulatory submissions and commercialization of PH94B neuroactive nasal spray for acute treatment of SAD, and potentially other anxiety-related indications, in markets in Greater China. EverInsight will make a non-dilutive upfront payment of $5M to VistaGen, and VistaGen is eligible to receive additional development and commercial milestone payments of up to $172M. VistaGen will receive tiered royalties on sales of PH94B in the Territory, if Phase 3 development efforts are successful. VistaGen retains exclusive rights to develop and commercialize PH94B in all markets outside the Territory.
Read more at:
https://thefly.com/landingPageNews.php?id=3116409
Yeah, I remember reading somewhere long ago that in some survey speaking in front of a group had ranked just below death by fire as what one fears most!
Huge market if these guys hit pay dirt, and with their tiny M/C...I figure it's worth a gamble even though they are likely to dilute significantly; upside seems huge...but I also haven't researched any competition.
Your OPK looking ready this afternoon.
Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development https://seekingalpha.com
Yikes! Has this been posted on their board yet? They all seem pretty excited over there.
He wants publicity. PERIOD. He’s on a friggin Twitter video with a time limit. With a wanna be know it all doctor. These aren’t biotech experts. I’m glad we got a mention but it means nothing. This isn’t an earth shattering event. Let’s stay focused.
This Twitter video from one doctor who likes to yack... yes, great publicity but in the big picture is a blip on the screen. Execs don’t even know or pay attention to this. We have bigger fish to fry. Trust in their professionalism and know what we have here.
Furthest along in phase 3.
BEST RESULTS to date.
HUGE PIPE.
Nasdaq
EUA or full FDA approval
Venrock
Valiant
Share structure
Etc
Etc
So if HGEN is 90% owned by insiders and the pps is being held back for institutional buyers once we get Nasdaq, what will that do to the float and pps once we do get Nasdaq approval (rhetorically)?
Oh yea, and Valiant owns over 27,000,000.
These are bigger than what iHuber’s refer to as whales.
https://sec.report/Document/0000935836-20-000338/?_gl=1*3mta4k*_ga*aDdqcXp6TllLajYwQVc5LUZxMDhyNVZGRERhY1FjcnlMdG9jelFMYnhTOERoTDJvcU5JbU13M2x4Yk9ndUpWZA..
I’ve had some doubt here over the past couple days but one thing that eases my mind (and the reason I added twice again today)which has been mentioned here many times -Venrock Capital Partners purchased 17,241,379 shares here. It was just filed on June 2nd. Please look at their track record. You will understand Venrock does not take shots in the dark at OTC garbage. Follow the money. Follow the track record. They very rarely lose... And they don’t look for $3 pps gains.